Figure 3: EPE peptide prevents proliferation of cancer but not normal cells.
From: The nuclear translocation of ERK1/2 as an anticancer target
(a) Effect of the EPE peptide on the proliferation of various cell lines. Sixteen cancer and four ‘normal’ immortalized cell lines were treated with either EPE or scrambled peptides as described above. Viable cells were quantified by methylene blue at 48 or 72 h after cell seeding. (b) Comparison of the effects of the EPE peptide and Raf inhibitor PLX4032 on cell viability. NHEM-Ad, LOXIMVI, A2352, HeLa MDA-MB-231 and DU-145 cells were treated either with EPE peptide, scrambled peptide (10 μM), PLX4032 (1 μM), DMSO control (0.1%) or no treatment at 1% fetal calf serum (FCS). Quantification of viable cells was detected as above. The graphs present the kinetic of cell growth at the indicated times. All experiments were repeated three times in triplicates. All results were presented as a fold change of the initial cell number obtained from three independent experiments and represent averages±standard errors.
